| Literature DB >> 27478309 |
Fang Liu1, Nan-Xia Xuan1, Song-Min Ying1, Wen Li1, Zhi-Hua Chen1, Hua-Hao Shen2.
Abstract
Asthma is one of the most common chronic inflammatory disorders, associated with reversible airflow obstruction, airway hyperresponsiveness, and airway remodeling. This disease has a significant impact on individuals, their families, and society. Standardized therapeutics such as inhaled corticosteroid in combination with long acting β2 agonist have been applied for asthma control; however, complementary and alternative medicines, especially herbal medicines, are still widely used all over the world. A growing body of literature suggests that various herbals or related products might be effective in inhibiting asthmatic inflammation. In this review, we summarize recent advances about the mechanistic studies of herbal medicines on allergic airway inflammation in animal models and their potential application into clinic for asthma control.Entities:
Mesh:
Year: 2016 PMID: 27478309 PMCID: PMC4958455 DOI: 10.1155/2016/6943135
Source DB: PubMed Journal: Mediators Inflamm ISSN: 0962-9351 Impact factor: 4.711
Details of basic researches included in the paper.
| Herbs | Material | Extracts | Asthmatic model | Route | Effective dose | Mechanism | |
|---|---|---|---|---|---|---|---|
| Category | Details | ||||||
|
| Root | Skullcapflavone II [ | OVA-induced Balb/c mice | Oral | 10, 30 mg/kg/d | TGF- | Reduced TGF- |
| Root | Baicalein [ | OVA-induced Balb/c mice | i.p. | 10 mg/kg/d | AAMP | Reduced 12/15-LOX activity | |
| NA | Oroxylin A [ | OVA-induced Balb/c mice | Oral | 15, 30, and 60 mg/kg/d | NF- | Suppressed NF- | |
| Specific IgE induced rat RBL-2H3 mast cells |
| 10, 30 | Mast cells | Inhibited degranulation of mast cells | |||
| Root | Wogonin [ | OVA-induced Balb/c mice | Oral | 10, 30 mg/kg/d | STAT6 | Suppressed OVA-induced STAT6 activation | |
| IL-4 induced BEAS-2B cells |
| 10, 30, and 50 | STAT6 | Suppressed IL-4-induced eotaxin-3 expression via suppressing JAK1 and STAT6 activation | |||
| Root | Baicalin [ | OVA-induced Balb/c mice | Oral | 25, 50, and 100 mg/kg/d | MAPK | Inhibited RASM cell proliferation and migration by suppressing MAPK signal pathway | |
| Airway smooth muscle cells from SD rats (RASM) |
| 10, 25, and 100 nM | |||||
|
| |||||||
|
| NA | Aqueous extract [ | OVA-induced C57BL/6 mice | Oral | 3 | GATA3/T-bet | Decreased the ratio of the GATA3/T-bet mRNA levels |
| Root | Astragaloside IV [ | OVA-induced Balb/c mice | Oral | 50, 150 mg/kg/d | GATA3/T-bet | Decreased the ratio of the GATA3/T-bet expression level | |
| OVA-induced Balb/c mice | Oral | 50, 150 mg/kg/d | — | Increased IFN- | |||
| OVA-induced Balb/c mice | Oral | 20, 40 mg/kg/d | Foxp3/ROR | Increased CD4+CD25+Foxp3+ Tregs and enhanced Foxp3 mRNA expression | |||
| OVA-induced Balb/c mice | Oral | 50 mg/kg/d | TGF- | (1) Reduced TGF- | |||
| NF- | (2) Inhibited TSLP expression | ||||||
| NA | Aqueous extract [ | OVA-induced SD rats | Oral | 5, 10 g/kg/d | Foxp3/ROR | Increased CD4+CD25+Foxp3+ Tregs and enhanced Foxp3+ mRNA expression | |
| NA | Aqueous extract [ | OVA-induced C57BL/6 mice | i.p. | 10 g/kg/d | — | Increased Th1/Th2 cytokines' ratio | |
| NA | Formononetin & calycosin [ | OVA-induced Balb/c mice | Oral | 0.5 g/kg/2 d | NF- | Suppressed NF- | |
|
| |||||||
|
| — | Astragali-Cordyceps suspensions [ | OVA-induced C57BL/6 mice | Oral | 6.5 g/kg/d | TGF- | Reduced TGF- |
|
| |||||||
|
| Root | Aqueous extract [ | OVA-induced C57BL/6 mice | i.p. | 20 mg/kg/d | MAPK | Inhibited CD40/CD40L ligation and MAPK signal pathway |
| Leaves | Purified aqueous extract (RG-II) [ | OVA-induced Balb/c mice | i.p. | 20, 100 mg/kg/d | GATA3/T-bet | Decreased the ratio of the GATA3/T-bet expression level | |
| Root | Aqueous extract (CVT-E002) [ | OVA-induced Balb/c mice | Oral | 200 mg/kg/d | Foxp3/ROR | Increased Tregs function and IL-10 level in BALF | |
| Root | Ginsan [ | OVA-induced Balb/c mice | i.p. | 100 mg/kg/2 d | AAMP | Upregulated COX-1 and COX-2 expression, leading to the increase of PGE2 in BALF | |
|
| |||||||
|
| Root | Saucerneol D [ | OVA-induced Balb/c mice | Oral | 20, 40 mg/kg/d | Antioxidant | Upregulated the expression of HO-1 |
| Aerial parts | A subfraction of ethanol extract [ | RAW264.7 cells derived from BALB/c mice |
| 5, 50 | Antioxidant | Upregulated the expression of HO-1 | |
| Aerial parts | Sauchinone [ | RAW264.8 cells derived from BALB/c mice |
| 2.5, 5, and 10 | Antioxidant | Upregulated the expression of HO-1 | |
| OVA-induced Balb/c mice | i.p. | 10, 100 mg/kg/2 d | GATA3/T-bet | Suppressed GATA-3 activity | |||
| Root | Meso-Dihydroguaiaretic acid [ | OVA-induced Balb/c mice | Oral | 10, 30 mg/kg | NF- | Inhibited Th2 inflammation via inhibiting NF- | |
| Aerial parts | 70% ethanol extract [ | Bone marrow-derived mast cells from Balb/c mice |
| 0.8–50 | AAMP | Inhibited LTC4 and PGD2 level | |
|
| |||||||
|
| NA | 70% ethanol extract [ | OVA-induced Balb/c mice | Oral | 2, 10, and 20 g/kg/d | — | Elevated the ratio of Th1/Th2 |
| AAMP | Decreased the cysLT1 mRNA levels | ||||||
|
| |||||||
|
| Aerial parts | Ethanol extract [ | OVA-induced Balb/c mice | Oral | 100 mg/kg/d | — | (1) Inhibit increases in IgE, IL-4, and IL-5 in BALF and lung tissue |
| Antioxidant | (2) Reduced the levels of ROS in BALF | ||||||
|
| |||||||
|
| Fructus | Aqueous extract [ | OVA-induced Balb/c mice | Oral | 10 g/kg/d | — | Inhibited the upregulation of IL-4 and IL-13 levels in BALF |
| Fructus | Psoralen [ | ConA stimulated D10.G4.1 cells |
| 0.08 mM | GATA3/T-bet | Suppressed the upregulation of IL-4, IL-5, IL-13, and GATA-3 protein expression | |
| Fructus | Bavachinin [ | OVA-induced Balb/c mice | Oral | 50 mg/kg/d | — | Suppressed IL-4, IL-5, and IL-13 in lung tissue and serum levels of IL-4, IgE | |
| ConA, IL-2, IL-4 stimulated 4GET mice spleen cells |
| 0.01 mM | GATA3/T-bet | Suppressed GATA-3 mRNA levels | |||
|
| |||||||
|
| NA | Astilbic acid [ | OVA-induced Balb/c mice | Oral | 30 mg/kg/d | NF- | Suppressed NF- |
|
| |||||||
|
| Flower | Crocetin [ | OVA-induced C57BL/6 mice | Intranasal | 3 | Foxp3/ROR | Increased Foxp3 through TIPE2 to activate Tregs |
| Flower | Crocin [ | OVA-induced Balb/c mice | Oral | 100 mg/kg/d | MAPK | Inhibited the expression of lung eotaxin, p-ERK, p-JNK, and p-p38 level | |
| Flower | Safranal [ | — | — | — | Relaxing ASM | Antihistamine and anticholinergic and | |
|
| |||||||
|
| NA | Dihydroartemisinin [ | OVA-induced Balb/c mice | Oral | 30 mg/kg/d | NF- | Inhibited Th2 inflammation via inhibiting NF- |
| NA | Artesunate [ | OVA-induced Balb/c mice | i.p. | 30 mg/kg/d | Antioxidant | Suppressed prooxidants and restoring expression of antioxidants via activation of Nrf-2 | |
|
| |||||||
|
| Leaves | Purified aqueous extract (AIP1) [ | OVA-induced Balb/c mice | i.p. | 5 mg/kg | Dendritic cell | Reduced levels of MHC II in dendritic cells |
|
| |||||||
|
| NA | Ligustrazine [ | OVA-induced C57BL/6 mice | i.p. | 80 mg/kg/d | GATA3/T-bet | (1) Decreased the ratio of the GATA3/T-bet expression level |
| Foxp3/ROR | (2) Increased the ratio of Foxp3/ROR | ||||||
|
| |||||||
|
| Whole | Aqueous extract [ | OVA-induced Balb/c mice | NA | 0.5, 1 g/kg/d | Foxp3/ROR | Inhibited the decrease of Tregs in BALF |
|
| |||||||
|
| NA | 80% ethanol extract [ | OVA-induced Balb/c mice | Oral | 500 mg/kg/d | — | (1) Inhibit increases in OVA-specific IgE and IL-5 in BALF |
| Antioxidant | (2) Reduced the levels of ROS in BALF | ||||||
| Leaves | Bakkenolide B [ | Rat RBL-2H3 mast cells & C57BL/6 mouse peritoneal macrophages |
| 1–10 | Mast cells | Inhibited degranulation in mast cells and suppressed iNOS in macrophages | |
| Leaves | Petatewalide B [ |
| 10, 30 | ||||
|
| |||||||
|
| Fructus | Osthol [ | IL-4/TNF- |
| 1–10 | STAT6 | Suppressed IL-4-induced eotaxin expression via suppressing STAT6 activation |
|
| |||||||
|
| Leaves | Fargesin and epimagnolin [ | A549 human alveolar epithelial cells |
| 3.1–100 | MAPK | Modulated NO synthesis via inhibiting ERK in human respiratory epithelial cells |
|
| |||||||
|
| NA | Esculentoside A (EsA) [ | OVA-induced Balb/c mice | i.p. | 15 mg/kg/d | Antioxidant | Reduced the levels of ROS in BALF |
| A549 human alveolar epithelial cells |
| 10, 20 mg/L | Antioxidant | Nrf-2 activator. Upregulated the expression of HO-1 | |||
|
| |||||||
|
| Oil | Diallyl-disulfide (DADS) [ | OVA-induced Balb/c mice | Oral | 30 mg/kg/d | Antioxidant | (1) Reduced the levels of ROS in BALF |
| NF- | (2) Suppressed NF- | ||||||
| RAW264.7 murine macrophage cell |
| 62.5–500 ng/mL | Antioxidant | Nrf-2 activator. Upregulated the expression of HO-1 | |||
|
| |||||||
|
| NA | Trifolirhizin [ | Tracheal rings of OVA-induced Balb/c mice |
| 6 | Relaxing ASM | Inhibiting acetylcholine mediated ASM contraction |
|
| |||||||
|
| Root | 70% methanol extract [ | Lung slices of Balb/c mice |
| 0.3, 1 mg/mL | Relaxing ASM | Inhibiting acetylcholine mediated ASM contraction via blocking Ca2+ channels |
|
| |||||||
|
| Root | 7-Oxo-sandaracopimaric acid [ | OVA-induced guinea pigs | Oral | 25–100 mg/kg | AAMP | Inhibiting phospholipase A2 (PLA2) eosinophil peroxidase (EPO) activity in BALF |
|
| |||||||
|
| Seed |
| OVA-induced guinea pigs | Oral | 2.5 mg/kg/d | — | (1) Decreased the levels of TNF- |
| Antihistamine | (2) Antihistamine | ||||||
|
| |||||||
|
| — | Aqueous extract [ | OVA-induced Balb/c mice | Oral | 100, 200 mg/kg/d | Antioxidant | Upregulated the expression of HO-1 |
|
| |||||||
|
| NA | Eucalyptol (1.8-cineole) [ | Monocytes from patients with asthma |
| 200 mg/d | AAMP | Inhibit LTB4 and PGE2 |
i.p. = intraperitoneal injection. AAMP = arachidonic acid metabolism pathway. TIPE2 = TNF-α-induced protein 8-like 2. NA = not available.